Month: August 2022

Sign up for only $19.99! On 24 August 2022, Singapore announced further relaxation of COVID-19 measures. Effective 29 August 2022, non-fully vaccinated travellers will be allowed to enter Singapore without applying for approval. In addition, wearing of mask is optional except on public transport and in healthcare facilities. These relaxations should further expedite the recovery of the travel-related sector, thereby benefitting S-REITs like OUE Commercial REIT.

Despite the positive developments, it is not going to be smooth sailing for OUE Commercial REIT as the operating environment has turned significantly dark. Obviously, the market is still reeling from the fallout arising from Russia invasion of Ukraine. Supply chain has been disrupted and inflation rates rocketed in many countries. Against this backdrop, US Federal Reserves has raised interest rates four times, bringing federal fund rate to between 2.25% and 2.5%.

A member of SG Wealth Builder has requested for a stock analysis of OUE Commercial REIT and sought my opinion on the management team’s competency. Year-to-date, the unit price has tanked by about 14.8% (at the point of writing). In terms of unit price performances, OUE Commercial REIT is easily one of the worst among the commercial S-REITs. What could be the factor for the bearish form?

Sign up for only $19.99! What a comeback! Following the release of a set of stellar 1HFY2022 financial result, Raffles Medical share price soared 17% within a week. The recovery of Raffles Medical share price must be surreal for investors as the counter collapsed spectacularly in February 2022 following the release of a set of decent financial result for FY2021.

The bearish form of Raffles Medical share price in late 2021 was attributed to the change in the COVID-19 test policy. Raffles Medical share (SGX: BSL) had ridden on the pandemic wave as the Group provides PCR swab tests services. Then again, it is always a risky business to pivot a business on pandemic measures.

In early 2022, Raffles Medical share price came under further pressure due to the lockdowns in China cities, which impacted the Group’s three hospitals in China. According to the management, Raffles Hospital Shanghai was the most impacted. To cushion the impact, the Group conducted a series of shares buybacks to rescue Raffles Medical share price. For the new financial year, the Group acquired 5.3 million of shares from the market. As at 28 June, the number of treasury shares held was 23.3 million.

Here’s why Raffles Medical share price plunged 12%

Raffles Medical share price in sensational return!

Sign up for only $19.99! Bring on the champagne! Light up the fireworks! AEM share price looks set for a splendid run after the Group delivered an incredibly stellar 1HFY2022 financial result. Revenue for 1H2022 surged by 181% year-on-year to $540.5 million, while net profit rocketed 180% year-on-year to smash $83 million. The first half revenue and net profit were the highest in the Group’s history.

Prior to the result release, many investors (including myself) have the jitters. After all, Intel has posted a brutal US$500 million loss in the second quarter, resulting in the company cutting back on expenditure. Nonetheless, AEM survived the scare to post a stellar financial result. While it is too early to claim that AEM has managed to weed off its reliance on Intel for revenue, the result could push AEM to expedite its effort in diversifying revenue source.

The patent obtained in July for the thermal control for its System Level Test equipment would give AEM the trump card in its negotiation with the top ten semiconductor companies. The contract wins from 2 major customers vindicated my belief that intellectual property is the way to win the battle.

The contract wins came from “a leading High-Performance Computing (“HPC”)/Artificial Intelligence (“AI”) company” and “a leading mobile devices company”.

Sign up for only $19.99! It could be peace before the perfect storm. Following the release of a decent set of financial result, the DBS share price has stalled somewhat. Rightfully, investors should have plenty to cheer about as the rising interest rates should provide power tailwinds for the bank’s business. Nonetheless, in today’s context, things aren’t always so straightforward.

Being the largest lender in Singapore, DBS’ business is sensitive to new property cooling measures. In the December 2021 cooling measures, the loan-to-value for HDB loans was tightened. However, it should be noted that round of cooling measures did not affect financial institution loans. As such, DBS housing loan portfolio has been resilient so far.

Fast forward to August 2022, the world has changed so much. Yes, the pandemic is still around but the invasion of Ukraine by Russia has created plenty of market chaos like never before. On the other hand, the US Federal Reserve is struggling to tame raging inflation by hiking interest rates. Despite these uncertainties, Singapore property market continued to defy gravity, with property prices sky-rocketing.

According to URA, prices of private residential properties increased by 3.5% in 2nd quarter of 2022, compared with the 0.7% increase in the previous quarter. 

Lifetime Membership On 21 July 2022, Mapletree Logistics Trust (SGX: M44U) delivered its 1QFY2022/2023 result. In view of this, its time to take stock the performance of the S-REIT. Unit price had tumbled following the US Federal Reserve interest rate hikes in March and May. Subsequently, it seems that the counter had bottomed in late May as unit price began to start climbing. The tepid unit price performances were attributed to the lack of buying by institutional investors. For the past 7 months, Mapletree Logistics Trust did not feature in the SGX Top Ten Institutional Net Buy Stocks.

The million-dollar question confronting investors right now must be whether Mapletree Logistics Trust (M44U) will launch another mega equity financing to fund its overseas logistics asset acquisitions. The $700 million equity fundraising in November 2021 to purchase the China, Vietnam and Japan assets had knocked the wind out of the unit price, which never returned to the $2.00 mark prior to the equity fundraising.

For background, the principal activity of MLT is to invest in a diversified portfolio of logistics real estate in Asia Pacific with the aim of providing its unitholders with a stable distribution stream. As at 30 June 2022, the Group’s portfolio had grown to a portfolio of 185 properties in Singapore, Australia, China, Hong Kong SAR, India, Japan, Malaysia, South Korea and Vietnam.

Lifetime Membership On 5 July 2022, AEM obtained the grant of patent for the thermal control technology used in its System Level Test equipment. Will this patent change the fortune of the semiconductor test equipment manufacturer? Following the fallouts from the Russia-Ukraine conflict and soaring interest rates, AEM share price has been in sluggish form in 2022. Year-to-date, AEM share price slumped by about 17%.

One should not underestimate the potential impact of the new patent on AEM share price. Non-executive Chairman Loke Wai San was the man who led AEM out of dark Egypt when the former management was embroiled in a corruption scandal in 2012. Back then, AEM share price was on the brink of collapse and the company had been placed on the SGX Watch-List.

Despite the challenges, Loke Wai San saw the potential in the equipment business due to the partnership with leading US chipmaker, Intel. The decision proved to be pivotal as the partnership between AEM and Intel led to a patent for its test handling stacking technology. The patent was granted in March 2018. If investors look back, AEM share price used to trade at less than $0.10 in 2016. The patent turbocharged AEM share price to nearly $2.00 in March 2018.